RxDoctor Payments Data

Milena Loukanova, MD

Internal Medicine · Fort Myers, FLNPI 1114927696

Payments from drug & device makers

$1,439in general payments, 2019–2025

Across 69 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$337
  • Amgen$192
  • AstraZeneca$187
  • Lilly USA, LLC$105
  • AbbVie$92
  • Astellas Pharma US Inc$78
  • plus $449 from 11 others

What the payments were for

  • Food & beverage$1,439100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,439 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$192,754
Medicare patients
467
Services billed
2,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$88,600
OzempicSemaglutide60$65,741
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$39,847
JanumetSitagliptin Phos/Metformin Hcl20$12,178
XareltoRivaroxaban11$10,852
Ibandronate Sodium105$4,177
Atorvastatin Calcium551$4,165
PremarinEstrogens, Conjugated12$4,150
Levothyroxine Sodium474$4,047
SynthroidLevothyroxine Sodium55$3,195
Ezetimibe100$2,900
PaxlovidNirmatrelvir/Ritonavir25$2,676
Omeprazole231$2,612
Amlodipine Besylate457$2,602
Rosuvastatin Calcium225$2,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$37$95,426115 claims
Novo NordiskOzempic$59$65,74160 claims
GSKTrelegy Ellipta$337$39,84754 claims
MerckJanumet$24$12,17820 claims
AbbVieSynthroid$92$3,19555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →